Clinical Trials on Myxoma

Total 3512 results

PregLem SA

Completed

PGL4001 Versus GnRH-agonist in Uterine Myomas (PEARLII)

Uterine Myomas

Spain, Germany, Austria, Israel, Poland, Italy, Belgium, France, Netherlands
University Magna Graecia
Johnson & Johnson

Completed

Randomized Controlled Trial (RCT)Comparing GYNAECARE MORCELLEX Versus ROTOCUT GI Tissue Morcellators

Uterine Myomas

Italy
Ospedale Policlinico San Martino

Recruiting

Predictive Factors for Complete Myoma Resection During Hysteroscopic Myomectomy

Uterine Fibroids | Uterine Myomas

Italy
PregLem SA

Completed

PGL4001 Versus Placebo in Uterine Myomas (PEARLI)

Uterine Myomas

Czech Republic, Hungary, India, Romania, Russian Federation, Ukraine
CHA University

Terminated

Hand-assisted Laparoscopic Surgery (HALS) for Myomectomy

Uterine Myomas

Korea, Republic of
CHA University

Completed

Vasopressin Versus Epinephrine in Myomectomy

Uterine Myomas

Korea, Republic of
Atatürk University
MSc Merve Eroğlu

Completed

The Pain and Anxiety in Children With Intramuscular Injection

Intramuscular Myxoma

Turkey
Seoul National University Bundang Hospital

Completed

Effect of Magnesium Sulphate on Coagulation

Myoma

Korea, Republic of
Terumo Europe N.V.

Completed

Assessment of the Manageability and Safety of ADBLOCK Adhesion Barrier System in Laparoscopic Gynaecological Surgery (ADBEE)

UTERINE MYOMAS

Germany
Taipei Veterans General Hospital, Taiwan
National Yang Ming University

Unknown

Single-port Access Laparoscopic-assisted Vaginal Hysterectomy

Adenomyosis | Uterine Myomas

Taiwan
Tianjin Eye Hospital

Completed

Vision Screening Study for College Students at Nankai University

Myoma

China
University Hospitals Cleveland Medical Center

Withdrawn

Paracervical Vasopressin Injection Compared With Intramyometrial Vasopressin in Abdominal Myomectomy

Myoma

United States
Ege University

Completed

Laparoscopic Enclosed Morcellation; Electromechanic Morcellation vs Vaginal Removal

Myoma

Turkey
National Cancer Center, Korea

Unknown

Pilot Study to Evaluate the Knowledge and Understanding on Surgery for Patients With Hysterectomy

Gynecologic Cancer | Myoma
Aswan University Hospital

Unknown

Topical Tranexamic Acid Plus Perivascular Vasopressin at the Time of Abdominal Myomectomy

Myoma

Egypt
Kangbuk Samsung Hospital

Completed

Temporary Simultaneous Two-arterial Occlusions During Laparoscopic Myomectomy (TESTO)

Myoma

Korea, Republic of
Lawson Health Research Institute
The Ottawa Hospital; Hamilton Health Sciences Corporation; Dalhousie University; Niagara Health System

Active, not recruiting

Rivaroxaban or Aspirin As Thromboprophylaxis in Multiple Myeloma (RithMM)

Multiple Myeloma in Relapse | Multiple Myeloma With Failed Remission | Multiple Myeloma Stage I | Multiple Myeloma Progression | Multiple Myeloma Stage II | Multiple Myeloma Stage III

Canada
Yonsei University

Completed

Pain Characteristics After Total Laparoscopic Hysterectomy

Myoma of Uterus

Korea, Republic of
Johnson & Johnson Pharmaceutical Research & Development...
PharmaMar

Completed

Safety and Efficacy Study of Trabectedin for the Treatment of Localized Myxoid / Round Cell Liposarcoma

Liposarcoma,Myxoid

France, United States, Germany
Tel-Aviv Sourasky Medical Center

Completed

Carfilzomib in Combination With Daratumumab, Lenalidomide and Dexamethasone in Transplant-ineligible NDMM Patients (KyDaR)

Plasma Cell Myeloma | Myeloma-Multiple | Myeloma Multiple | Myeloma, Plasma-Cell

Israel
The Netherlands Cancer Institute

Unknown

Dose Reduction of Preoperative Radiotherapy in Myxoid Liposarcomas (DOREMY)

Myxoid Liposarcoma of Soft Tissue

Netherlands, United Kingdom, Norway, United States, Denmark
Far Eastern Memorial Hospital

Recruiting

Clinical Outcomes of Robotic Myomectomy

Women With Uterine Myoma

Taiwan
Albert Einstein College of Medicine
National Cancer Institute (NCI)

Terminated

Desipramine Hydrochloride and Filgrastim For Stem Cell Mobilization in Patients With Multiple Myeloma Undergoing Stem Cell Transplant

Refractory Plasma Cell Myeloma | DS Stage II Plasma Cell Myeloma | DS Stage III Plasma Cell Myeloma | DS (Durie/Salmon) Stage I Plasma Cell Myeloma

United States
Albert Einstein College of Medicine
National Cancer Institute (NCI)

Completed

Busulfan, Melphalan, and Bortezomib Before First-Line Stem Cell Transplant in Treating Patients With Multiple Myeloma

Refractory Plasma Cell Myeloma | DS Stage I Plasma Cell Myeloma | DS Stage II Plasma Cell Myeloma | DS Stage III Plasma Cell Myeloma

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Lenalidomide, Dexamethasone, and Clarithromycin in Treating Patients Who Have Undergone Stem Cell Transplant for Multiple Myeloma

Refractory Plasma Cell Myeloma | DS Stage I Plasma Cell Myeloma | DS Stage II Plasma Cell Myeloma | DS Stage III Plasma Cell Myeloma

United States
National Cancer Institute (NCI)

Active, not recruiting

Lenalidomide in Treating Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant

Smoldering Multiple Myeloma | Refractory Multiple Myeloma | DS Stage I Multiple Myeloma | DS Stage II Multiple Myeloma | DS Stage III Multiple Myeloma

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Bortezomib, Melphalan, and Total-Body Irradiation Before Stem Cell Transplant in Treating Patients With Multiple Myeloma

Refractory Plasma Cell Myeloma | DS Stage I Plasma Cell Myeloma | DS Stage II Plasma Cell Myeloma | DS Stage III Plasma Cell Myeloma

United States
National Cancer Institute (NCI)

Completed

Vismodegib After Stem Cell Transplant in Treating Patients With High-Risk First Remission or Relapsed Multiple Myeloma

Refractory Plasma Cell Myeloma | DS Stage I Plasma Cell Myeloma | DS Stage II Plasma Cell Myeloma | DS Stage III Plasma Cell Myeloma

United States
US Oncology Research
Karyopharm Therapeutics Inc

Recruiting

Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma

Multiple Myeloma | Plasma Cell Myeloma | Myeloma-Multiple | Myeloma Multiple | Kahler Disease | Myeloma, Plasma Cell | Myelomatosis

United States
University of Washington
National Cancer Institute (NCI)

Terminated

Pegylated Liposomal Doxorubicin Hydrochloride, Bortezomib, Cyclophosphamide, and Dexamethasone in Treating Patients With Multiple Myeloma

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple Myeloma

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Thalidomide, Dexamethasone, and Clarithromycin in Treating Patients With Multiple Myeloma Previously Treated With Transplant

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple Myeloma

United States
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Terminated

High Dose Busulfan and Bortezomib in Treating Patients With High Risk Multiple Myeloma Undergoing Stem Cell Transplant

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Completed

Vorinostat and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple Myeloma

United States
Fred Hutchinson Cancer Research Center/University...
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Multiple Myeloma Who Have Undergone Stem Cell Transplantation

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple Myeloma

United States
Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Terminated

Lenalidomide After Donor Stem Cell Transplant and Bortezomib in Treating Patients With High Risk Multiple Myeloma

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple Myeloma

United States
Mayo Clinic

Completed

Plerixafor in Treating Patients With Multiple Myeloma Previously Treated With Lenalidomide and Planning to Undergo Autologous Stem Cell Transplant

Multiple Myeloma | Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Terminated

Obatoclax and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Completed

Sunitinib in Treating Patients With Relapsed Multiple Myeloma

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple Myeloma

United States
City of Hope Medical Center

Completed

Plerixafor and Filgrastim Following Cyclophosphamide for Stem Cell Mobilization in Patients With Multiple Myeloma

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple Myeloma

United States
University of Cagliari
Azienda Ospedaliera Ordine Mauriziano di Torino; University of Foggia; Civic... and other collaborators

Recruiting

OPPIuM Technique and Myolysis With Diode Laser Dwls (Myolysis)

Uterine Fibroid | Myoma;Uterus

Italy
Emory University
National Cancer Institute (NCI); Merck Sharp & Dohme LLC; National Institutes...

Completed

Pembrolizumab and Radiation Therapy in Patients With Relapsed or Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma | ISS Stage III Plasma Cell Myeloma | ISS Stage II Plasma Cell Myeloma | ISS Stage I Plasma Cell Myeloma

United States
Wael Elbanna Clinic

Recruiting

The Effect of Intramyometrial Injection of Terlipressin Versus Carbitocin on Hemoglobin and Blood Loss During Open Myomectomy Operations Without Using Haemostatic Tourniquets (myomectomy)

Myoma

Egypt
Wael Elbanna Clinic

Recruiting

The Effect of Intracapsular Injection of Terlipressin Versus Carbitocin on Hemoglobin and Blood Loss During Laparoscopic Myomectomy Operations

Myoma

Egypt
Aljazeera Hospital
Cairo University

Unknown

Safety of Tranexamic Acid in Reducing Blood Loss Myomectomy.

Myoma

Egypt
University Hospital, Ghent

Completed

The Hysteroscopic Morcellator (HM). (HM)

Large Intrauterine Polyps | Smaller Type 0 and 1 Myomas | Residual Placental Tissue

Belgium, Netherlands
University of Pennsylvania
Parker Institute for Cancer Immunotherapy; Tmunity Therapeutics

Terminated

NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells)

Melanoma | Multiple Myeloma | Myxoid/Round Cell Liposarcoma | Synovial Sarcoma

United States
Brugmann University Hospital

Withdrawn

Comparing Intra Uterine Synechiae Occurence Using Bipolar Energy Compared With Monopolar Energy in Myoma Resection on Women Having Menorraghia and/or Infertility

Symptomatic Submucosal Myoma

Belgium, France
Roswell Park Cancer Institute

Recruiting

Non-chemotherapeutic Interventions for the Improvement of Quality of Life and Immune Function in Patients With Multiple Myeloma

Plasma Cell Myeloma | Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma | Smoldering Plasma Cell Myeloma

United States
Yonsei University

Completed

Analgesic Effect of Trigger Point Injection and EMLA for Shoulder Pain in Laparoscopic Hysterectomy

Myoma of Uterus

Korea, Republic of
Alfred Chung, MD
Merck Sharp & Dohme LLC

Terminated

Pembrolizumab for the Treatment of Relapsed or Refractory Multiple Myeloma After Anti-BCMA CAR-T Therapies

Multiple Myeloma | Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma | Multiple Myeloma in Relapse | Multiple Myeloma, Refractory

United States

Clinical Trials on Myxoma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Luxembourg

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations